Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLK OTCMKTS:BETRF OTCMKTS:IGXT NASDAQ:SNYR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLKAllakos$0.33$0.33$0.22▼$1.56$29.74M0.151.21 million shsN/ABETRFBetterLife Pharma$0.06+5.3%$0.07$0.05▼$0.15$7.88M1.4512,219 shs23,728 shsIGXTIntelGenx Technologies$0.17$0.17$0.09▼$0.22$29.17M2.47N/AN/ASNYRSynergy CHC$3.30-2.1%$2.25$0.36▼$10.00$30.98MN/A103,346 shs39,141 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLKAllakos0.00%0.00%0.00%+3.49%-55.06%BETRFBetterLife Pharma+5.00%+0.33%-6.16%+10.33%-49.25%IGXTIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%SNYRSynergy CHC+4.01%+18.25%+60.48%+68.50%+1,673.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLKAllakos3.0261 of 5 stars3.10.00.04.70.62.51.3BETRFBetterLife PharmaN/AN/AN/AN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ASNYRSynergy CHC3.2344 of 5 stars3.80.00.00.00.03.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLKAllakos 2.25Hold$2.00507.72% UpsideBETRFBetterLife Pharma 0.00N/AN/AN/AIGXTIntelGenx Technologies 0.00N/AN/AN/ASNYRSynergy CHC 3.50Strong Buy$10.00203.03% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLKAllakosN/AN/AN/AN/A$1.93 per shareN/ABETRFBetterLife PharmaN/AN/AN/AN/A($0.04) per shareN/AIGXTIntelGenx Technologies$1.04M28.05N/AN/A($0.07) per share-2.39SNYRSynergy CHC$34.83M0.87$0.26 per share12.67($1.91) per share-1.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLKAllakos-$185.70M-$1.32N/AN/AN/AN/A-140.87%-86.22%8/6/2025 (Estimated)BETRFBetterLife Pharma-$2.55M-$0.01N/A∞N/AN/AN/A-609.07%9/23/2025 (Estimated)IGXTIntelGenx Technologies-$9.93M-$0.06N/A∞N/AN/AN/AN/AN/ASNYRSynergy CHC$2.12MN/A0.005.59N/AN/A-8.48%12.75%N/ALatest BETRF, SNYR, ALLK, and IGXT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SNYRSynergy CHC$0.07$0.10+$0.03$0.10$9.03 million$8.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLKAllakosN/AN/AN/AN/AN/ABETRFBetterLife PharmaN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/ASNYRSynergy CHCN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLKAllakosN/A6.086.08BETRFBetterLife PharmaN/A0.040.04IGXTIntelGenx TechnologiesN/AN/AN/ASNYRSynergy CHCN/A1.911.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLKAllakos84.64%BETRFBetterLife Pharma0.01%IGXTIntelGenx TechnologiesN/ASNYRSynergy CHCN/AInsider OwnershipCompanyInsider OwnershipALLKAllakos16.12%BETRFBetterLife Pharma34.77%IGXTIntelGenx Technologies42.05%SNYRSynergy CHC56.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLKAllakos19090.38 million74.94 millionOptionableBETRFBetterLife Pharma7129.46 million84.45 millionNot OptionableIGXTIntelGenx Technologies38174.66 million101.21 millionNot OptionableSNYRSynergy CHC409.19 million3.99 millionN/ABETRF, SNYR, ALLK, and IGXT HeadlinesRecent News About These CompaniesSynergy CHC Expands Retail Presence in North AmericaJune 30, 2025 | tipranks.comSynergy CHC Corp. (SNYR) Stock Price Today - WSJJune 24, 2025 | wsj.comSynergy CHC (NASDAQ: SNYR) Expands FOCUSfactor® to UAE & Turkey — Ignites Global Growth and New Revenue StreamsJune 18, 2025 | finance.yahoo.comSynergy CHC Corp. Expands International Licensing Deal with Gravity Pharma to Include Turkey, Securing $2 Million in RevenueJune 18, 2025 | quiverquant.comQHere is What You Need to Know Before Investing in Synergy CHC Corp. (SNYR)June 18, 2025 | finance.yahoo.comHere is What You Need to Know Before Investing in Synergy CHC Corp. (SNYR)June 16, 2025 | insidermonkey.comSynergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Jack Ross Buys 9,400 SharesJune 12, 2025 | insidertrades.comNew to The Street TV Spotlights Synergy CHC (NASDAQ:SNYR) as Former Coca-Cola Executive Joins to Drive FOCUSfactor(R) Energy Drink’s Global ExpansionJune 11, 2025 | freep.comFNew to The Street TV Spotlights Synergy CHC (NASDAQ:SNYR) as Former Coca-Cola Executive Joins to Drive FOCUSfactor(R) Energy Drink's Global ExpansionJune 10, 2025 | guardonline.comGSynergy CHC Corp. Appoints Damian Marano as Vice President of Beverage to Accelerate Functional Beverage ExpansionJune 10, 2025 | quiverquant.comQSynergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Help Drive FOCUSfactor Energy Drink Global ExpansionJune 10, 2025 | globenewswire.comSynergy CHC secures $20 million loan for growth and debt repaymentJune 5, 2025 | investing.comSynergy CHC Secures $20 Million Loan AgreementJune 4, 2025 | msn.comSynergy CHC Announces New $20 Million Long-Term Credit FacilityJune 4, 2025 | globenewswire.comSNYR Synergy CHC Corp.May 30, 2025 | seekingalpha.comSynergy CHC Announces Appointment of Erik Shields as Vice President of BeverageMay 29, 2025 | finance.yahoo.comSynergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Jack Ross Buys 5,000 SharesMay 22, 2025 | insidertrades.comAnalysts Offer Insights on Consumer Goods Companies: Wilmar International (OtherWLMIF) and Synergy CHC (SNYR)May 21, 2025 | theglobeandmail.comSynergy CHC Corp (SNYR) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges with ...May 16, 2025 | uk.finance.yahoo.comSynergy CHC Corp. Reports Strong Q1 2025 EarningsMay 15, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBETRF, SNYR, ALLK, and IGXT Company DescriptionsAllakos NASDAQ:ALLK$0.33 0.00 (0.00%) As of 05/15/2025Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.BetterLife Pharma OTCMKTS:BETRF$0.06 +0.00 (+5.25%) As of 02:34 PM EasternBetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.IntelGenx Technologies OTCMKTS:IGXT$0.17 0.00 (0.00%) As of 05/27/2025IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.Synergy CHC NASDAQ:SNYR$3.30 -0.07 (-2.08%) As of 04:00 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
